Advances in Drug Discovery: From Human Genetic Signatures to Drug Targets – Hosted by JLabs

Johnson & Johnson Innovation will host a virtual scientific and partnering event on state-of-the-art developments in translational sciences, bringing together entrepreneurs, start-ups, researchers, and scientists from across Europe, the US, and beyond.

Effective and robust human healthcare solutions are embedded in our collective and individual genetic make-up. Using large datasets such as the UK Biobank Whole Genome Sequencing programme we are increasingly able to identify genetic signatures relating to disease states (source). However, this association is only the start of the journey. We need to drill down from these genetic and phenotypic associations to identify the function of those genes and then to the products of those genes which are causal for disease. Translating these human genetic signatures to causal inference underpins research activities across the life sciences industry.

Johnson & Johnson Innovation, in collaboration with Janssen Research & Development, is seeking to gather entrepreneurs, biotechs and academic researchers who seek solutions to these questions for a discussion on harnessing the next wave of science and innovation in translating human genetic signatures.